BenzingaOctober 16, 2026 at 2:13 AM NY11 Days Ago
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
